You are here

Antibiotic Combo Ceftolozane/Tazobactam Seeks Regulatory Approval

Treatment targets urinary tract and intra-abdominal infections

A new drug application (NDA) has been submitted to the FDA for approval of the investigational antibiotic ceftolozane/tazobactam (Cubist Pharmaceuticals) for the treatment of complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs).

The NDA submission was based on positive data from pivotal phase III clinical trials in patients with cUTIs and cIAIs, which met primary endpoints that were agreed upon with the FDA.

In 2013, the FDA granted ceftolozane/tazobactam “fast track” status for the indications of cUTI and cIAI, as well as hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Ceftolozane/tazobactam, an antibiotic candidate being developed to treat certain Gram-negative infections, consists of ceftolozane (a cephalosporin that has demonstrated potent in vitro activity against Pseudomonas aeruginosa) with tazobactam (a well-established beta-lactamase inhibitor). The addition of tazobactam broadens coverage to include most extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli, Klebsiella pneumoniae, and other Enterobacteriaceae.

In pivotal phase III trials of ceftolozane/tazobactam versus levofloxacin in patients with cUTIs, and of ceftolozane/tazobactam in combination with metronidazole versus meropenen in patients with cIAIs, ceftolozane/tazobactam met its primary endpoints of statistical non-inferiority.

Highly adaptive pathogens that can develop resistance through several mechanisms, treatment-resistant Gram-negative bacteria are a serious global public health concern. Collectively, E. coli, K. pneumoniae, and P. aeruginosa account for 27% of all pathogens and 70% of all Gram-negative pathogens causing health care-associated infections.

Gram-negative bacteria are common causes of IAIs, UTIs, and nosocomial pneumonia, as well as bacteremia. E. coli is the most common cause of UTIs, and P. aeruginosa is the most common Gram-negative organism causing VABP. In addition, P. aeruginosa is the second most common cause of catheter-associated UTIs.

Source: Cubist Pharmaceuticals; April 21, 2014.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs